Status:

RECRUITING

Endometriosis Transcriptomic Cell Atlas

Lead Sponsor:

University Hospital, Toulouse

Collaborating Sponsors:

Institut National de la Santé Et de la Recherche Médicale, France

Conditions:

Endometriosis

Infertility

Eligibility:

FEMALE

18-45 years

Phase:

NA

Brief Summary

Endometriosis is an estrogen-dependent, chronic inflammatory gynecologic disease affecting women of reproductive age, with a therapeutic wandering of 6 to 10 years. A better understanding of the initi...

Detailed Description

Using tissues collected at different phases of menstrual cycle in healthy women and patients operated for endometriotic lesions, 3 main objectives : 1. To characterize cellular heterogeneity between ...

Eligibility Criteria

Inclusion

  • Patients over 18 and under 45 years of age
  • Patients with multiple endometriosis sites (superficial, deep and endometriomas) with an indication for surgery to treat disabling painful symptoms and stage III or IV endometriosis in the context of infertility.
  • Healthy patients including those operated on between the ages of 18 and 45 for tubal ligation
  • Healthy patients operated on between the ages of 18 and 45 for hysterectomies for benign causes other than endometriosis or adenomyosis
  • Patients operated on strictly at the time of menstruation
  • Participants who have not been on hormonal treatment for 2 months
  • Participant having signed the free and informed consent form
  • Membership of a Social Security scheme or equivalent

Exclusion

  • Patients with endometriosis non-surgically treated
  • Patients with endometriosis receiving hormonal treatment at the time of surgery or having received hormonal treatment in the 2 months prior to surgery
  • Patients with adenomyosis only
  • Healthy non-endometriotic patients undergoing hysterectomy for infectious or malignant causes
  • Patients benefiting from a legal protection measure (guardianship, curatorship, safeguard of justice)
  • Patients with positive serology for human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), hepatitis B (HBV) and hepatitis C (HCV)

Key Trial Info

Start Date :

September 27 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2027

Estimated Enrollment :

92 Patients enrolled

Trial Details

Trial ID

NCT06502548

Start Date

September 27 2024

End Date

September 1 2027

Last Update

April 10 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital Toulouse

Toulouse, France